Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 13.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,867 shares of the biotechnology company’s stock after acquiring an additional 4,640 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Arrowhead Pharmaceuticals were worth $1,112,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARWR. Pacer Advisors Inc. increased its stake in Arrowhead Pharmaceuticals by 79.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,119 shares of the biotechnology company’s stock valued at $493,000 after purchasing an additional 7,150 shares during the period. Washington Trust Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. China Universal Asset Management Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 351.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,429 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 9,676 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $443,000. Finally, Friedenthal Financial acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $51,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock traded up $0.03 during trading on Tuesday, reaching $28.78. 656,535 shares of the company were exchanged, compared to its average volume of 1,288,665. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $20.67 and a 52-week high of $39.83. The company has a market cap of $3.57 billion, a P/E ratio of -6.79 and a beta of 0.94. The stock’s 50 day moving average price is $25.53 and its 200 day moving average price is $28.01.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same quarter in the previous year, the company posted $0.45 earnings per share. The firm’s quarterly revenue was down 100.0% compared to the same quarter last year. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ARWR. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. The Goldman Sachs Group began coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 5th. They set a “neutral” rating and a $31.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 16th. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $43.25.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total value of $237,480.32. Following the sale, the insider now owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Victoria Vakiener sold 1,799 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the transaction, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the transaction, the insider now directly owns 127,107 shares in the company, valued at approximately $3,213,264.96. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.